Agonistic autoantibodies directed against G-protein-coupled receptors and their relationship to cardiovascular diseases
- PMID: 24777744
- DOI: 10.1007/s00281-014-0425-9
Agonistic autoantibodies directed against G-protein-coupled receptors and their relationship to cardiovascular diseases
Abstract
Agonistic autoantibodies (AABs) against G-protein-coupled receptor (GPCR) are present mainly in diseases of the cardiovascular system or in diseases associated with cardiovascular disturbances. The increasing knowledge about the role of autoantibodies against G-protein-coupled receptor (GPCR-AABs) as pathogenic drivers, the resulting development of strategies aimed at their removal or neutralization, and the evidenced patient benefit associated with such therapies have created the need for a summary of GPCR-AAB-associated diseases. Here, we summarize the present knowledge about GPCR-AABs in cardiovascular diseases. The identity of the GPCR-AABs and their prevalence in each of several specific cardiovascular diseases are documented. The structure of GPCR is also briefly discussed. Using this information, differences between classic agonists and GPCR-AABs in their GPCR binding and activation are presented and the resulting pathogenic consequences are discussed. Furthermore, treatment strategies that are currently under study, most of which are aimed at the removal and in vivo neutralization of GPCR-AABs, are indicated and their patient benefits discussed. In this context, immunoadsorption using peptides/proteins or aptamers as binders are introduced. The use of peptides or aptamers for in vivo neutralization of GPCR-AABs is also described. Particular attention is given to the GPCR-AABs directed against the adrenergic beta1-, beta2-, and α1-receptor as well as the muscarinic receptor M2, angiotensin II-angiotensin receptor type I, endothelin1 receptor type A, angiotensin (1-7) Mas-receptor, and 5-hydroxytryptamine receptor 4. Among the diseases associated with GPCR-AABs, special focus is given to idiopathic dilated cardiomyopathy, Chagas' cardiomyopathy, malignant and pulmonary hypertension, and kidney diseases. Relationships of GPCR-AABs are indicated to glaucoma, peripartum cardiomyopathy, myocarditis, pericarditis, preeclampsia, Alzheimer's disease, Sjörgren's syndrome, and metabolic syndrome after cancer chemotherapy.
Similar articles
-
Aptamer BC007 for neutralization of pathogenic autoantibodies directed against G-protein coupled receptors: A vision of future treatment of patients with cardiomyopathies and positivity for those autoantibodies.Atherosclerosis. 2016 Jan;244:44-7. doi: 10.1016/j.atherosclerosis.2015.11.001. Epub 2015 Nov 10. Atherosclerosis. 2016. PMID: 26584137
-
Cardiomyopathy - An approach to the autoimmune background.Autoimmun Rev. 2017 Mar;16(3):269-286. doi: 10.1016/j.autrev.2017.01.012. Epub 2017 Feb 2. Autoimmun Rev. 2017. PMID: 28163240 Review.
-
Aptamer neutralization of beta1-adrenoceptor autoantibodies isolated from patients with cardiomyopathies.Circ Res. 2011 Oct 14;109(9):986-92. doi: 10.1161/CIRCRESAHA.111.253849. Epub 2011 Aug 25. Circ Res. 2011. PMID: 21868696
-
Functional autoantibody diseases: Basics and treatment related to cardiomyopathies.Front Biosci (Landmark Ed). 2019 Jan 1;24(1):48-95. doi: 10.2741/4709. Front Biosci (Landmark Ed). 2019. PMID: 30468647 Review.
-
Functional autoantibodies in patients with different forms of dementia.PLoS One. 2018 Mar 14;13(3):e0192778. doi: 10.1371/journal.pone.0192778. eCollection 2018. PLoS One. 2018. PMID: 29538413 Free PMC article. Clinical Trial.
Cited by
-
Increased testosterone and proinflammatory cytokines in patients with polycystic ovary syndrome correlate with elevated GnRH receptor autoantibody activity assessed by a fluorescence resonance energy transfer-based bioassay.Endocrine. 2021 Oct;74(1):163-171. doi: 10.1007/s12020-021-02761-7. Epub 2021 May 20. Endocrine. 2021. PMID: 34013495 Free PMC article.
-
Glaucoma and Alzheimer: Neurodegenerative disorders show an adrenergic dysbalance.PLoS One. 2022 Oct 6;17(10):e0272811. doi: 10.1371/journal.pone.0272811. eCollection 2022. PLoS One. 2022. PMID: 36201426 Free PMC article.
-
The non-biphenyl-tetrazole angiotensin AT1 receptor antagonist eprosartan is a unique and robust inverse agonist of the active state of the AT1 receptor.Br J Pharmacol. 2018 Jun;175(12):2454-2469. doi: 10.1111/bph.14213. Epub 2018 May 6. Br J Pharmacol. 2018. PMID: 29570771 Free PMC article.
-
Effect of prazosin on diabetic nephropathy patients with positive α1-adrenergic receptor autoantibodies and refractory hypertension.Exp Ther Med. 2015 Jan;9(1):177-182. doi: 10.3892/etm.2014.2036. Epub 2014 Oct 27. Exp Ther Med. 2015. PMID: 25452798 Free PMC article.
-
Increased circulating β2-adrenergic receptor autoantibodies are associated with smoking-related emphysema.Sci Rep. 2017 Mar 6;7:43962. doi: 10.1038/srep43962. Sci Rep. 2017. PMID: 28262783 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources